Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe
Sail Abusaif
Thomas K Eigentler

Showing results (1-10 of 454) with videos related to

Pageof 46
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
VemurafenibClaus Garbe, Sail Abusaif, Thomas K Eigentler
Melanoma Research|August 3, 2013
S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanomaSail Abusaif, Zeinab Jradi, Laura Held, et al.
Melanoma Research|May 15, 2007
Diagnosis and treatment of cutaneous melanoma: state of the art 2006Claus Garbe, Thomas K Eigentler
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
VemurafenibClaus Garbe, Thomas K Eigentler
Expert Opinion on Pharmacotherapy|September 3, 2013
Protein kinase inhibitors in melanomaThomas K Eigentler, Friedegund Meier, Claus Garbe
The Lancet. Oncology|December 10, 2003
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsThomas K Eigentler, Ulrich M Caroli, Peter Radny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2004
Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological societyUlrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma RegistryThomas K Eigentler, Petra G Buettner, Ulrike Leiter, et al.
Cancer|January 5, 2005
Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological SocietyPetra G Buettner, Ulrike Leiter, Thomas K Eigentler, et al.
British Journal of Cancer|June 29, 2018
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodiesNikolaus B Wagner, Andrea Forschner, Ulrike Leiter, et al.
Pageof 46

Showing results (1-10 of 454) with videos related to

Sort By:
Pageof 46
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
VemurafenibClaus Garbe, Sail Abusaif, Thomas K Eigentler
Melanoma Research|August 3, 2013
S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanomaSail Abusaif, Zeinab Jradi, Laura Held, et al.
Melanoma Research|May 15, 2007
Diagnosis and treatment of cutaneous melanoma: state of the art 2006Claus Garbe, Thomas K Eigentler
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
VemurafenibClaus Garbe, Thomas K Eigentler
Expert Opinion on Pharmacotherapy|September 3, 2013
Protein kinase inhibitors in melanomaThomas K Eigentler, Friedegund Meier, Claus Garbe
The Lancet. Oncology|December 10, 2003
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsThomas K Eigentler, Ulrich M Caroli, Peter Radny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2004
Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological societyUlrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma RegistryThomas K Eigentler, Petra G Buettner, Ulrike Leiter, et al.
Cancer|January 5, 2005
Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological SocietyPetra G Buettner, Ulrike Leiter, Thomas K Eigentler, et al.
British Journal of Cancer|June 29, 2018
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodiesNikolaus B Wagner, Andrea Forschner, Ulrike Leiter, et al.
Pageof 46